Immatics NV (IMTX)

NASDAQ
9.05
0.00(0.00%)
  • Volume:
    187,090
  • Day's Range:
    8.76 - 9.10
  • 52 wk Range:
    5.75 - 14.90

IMTX Overview

Prev. Close
9.05
Day's Range
8.76-9.1
Revenue
146.91M
Open
8.93
52 wk Range
5.75-14.9
EPS
0.437
Volume
187,090
Market Cap
594.83M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
266,185
P/E Ratio
40.40
Beta
0.394
1-Year Change
-33.75%
Shares Outstanding
65,726,816
Next Earnings Date
Dec 07, 2022
What is your sentiment on Immatics NV?
or
Market is currently closed. Voting is open during market hours.

Immatics NV News

Welcome to Your News Upgrade

Be the First to Know and Act on Market Moving News.

Welcome to Your News Upgrade

Immatics NV Company Profile

Immatics NV Company Profile

Employees
331

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company’s TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.

Read More

Analyst Price Target

Average22.83 (+152.30% Upside)
High30
Low14
Price9.05
No. of Analysts6
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Analysts 12-Month Price Target

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong BuyBuyNeutralStrong SellStrong Sell
Technical IndicatorsStrong BuyStrong BuyBuyStrong SellStrong Sell
SummaryStrong BuyStrong BuyNeutralStrong SellStrong Sell